Journal of Cancer Research and Clinical Oncology, том 147, издание 1, номера страниц: 49-59

Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors

Lazarevich Natalia L. 2, 3
Kustova Inna F. 2
Shavochkina Daria A. 2
Moroz Ekaterina A. 4
Kudashkin Nikolay E. 4
Patyutko Yuriy I. 4
Metelin Alexey V. 5
Kim Eduard F. 5
Zatsepin Timofei S. 1, 6
Тип документаJournal Article
Дата публикации2020-09-12
ИздательSpringer Nature
Название журналаJournal of Cancer Research and Clinical Oncology
Квартиль по SCImagoQ1
Квартиль по Web of ScienceQ2
Импакт-фактор 20214.32
ISSN01715216, 14321335
Cancer Research
Oncology
General Medicine
Краткое описание
Purpose Liver cancers are among the deadliest malignancies due to a limited efficacy of early diagnostics, the lack of appropriate biomarkers and insufficient discrimination of different types of tumors by classic and molecular methods. In this study, we searched for novel long non-coding RNA (lncRNA) as well as validated several known candidates suitable as probable biomarkers for primary liver tumors of various etiology. Methods We described a novel lncRNA HELIS (aka “HEalthy LIver Specific”) and estimated its expression by RT-qPCR in 82 paired tissue samples from patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), combined HCC-CCA, pediatric hepatoblastoma (HBL) and non-malignant hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH). Additionally, we examined expression of cancer-associated lncRNAs HULC, MALAT1, UCA1, CYTOR, LINC01093 and H19, which were previously studied mainly in HCC. Results We demonstrated that down-regulation of HELIS strongly correlates with carcinogenesis; whereas in tumors with non-hepatocyte origin (HBL, CCA) or in a number of poorly differentiated HCC, this lncRNA is not expressed. We showed that recently discovered LINC01093 is dramatically down-regulated in all malignant liver cancers; while in benign tumors LINC01093 expression is just twice decreased in comparison to adjacent samples. Conclusion Our study revealed that among all measured biomarkers only down-regulated HELIS and LINC01093, up-regulated CYTOR and dysregulated HULC are perspective for differential diagnostics of liver cancers; whereas others demonstrated discordant results and cannot be considered as potential universal biomarkers for this purpose.
Пристатейные ссылки: 62
Цитируется в публикациях: 9
A Review on the Update of Combined Hepatocellular Cholangiocarcinoma
Komuta M., Yeh M.M.
Q1 Seminars in Liver Disease 2019 цитирований: 7
The Role of Non-coding RNAs in Oncology
Slack F.J., Chinnaiyan A.M.
Q1 Cell 2019 цитирований: 284
Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics
Ning B., Yu D., Yu A.
Q1 Biochemical Pharmacology 2019 цитирований: 14
The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma
Wei L., Wang X., Lv L., Liu J., Xing H., Song Y., Xie M., Lei T., Zhang N., Yang M.
Q1 Molecular Cancer 2019 цитирований: 167
Open Access
Open access
Long Non-Coding RNA in the Pathogenesis of Cancers
Chi, Wang, Wang, Yu, Yang
Q1 Cells 2019 цитирований: 352
Open Access
Open access
Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies
Pardini B., Sabo A.A., Birolo G., Calin G.A.
Q1 Cancers 2019 цитирований: 87
Open Access
Open access
Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer
Jiang N., Pan J., Fang S., Zhou C., Han Y., Chen J., Meng X., Jin X., Gong Z.
Q1 Clinica Chimica Acta 2019 цитирований: 23
Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma
Lim L.J., Wong S.Y., Huang F., Lim S., Chong S.S., Ooi L.L., Kon O.L., Lee C.G.
Q1 Cancer Research 2019 цитирований: 94
Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma
John Lu Z., Zhang T., Yin J., Wang D., Ma L., Yang L., Zhu Y., Wang S., Xi X., Chen L., Cao J., Tan C.
Q1 Clinical Chemistry 2019 цитирований: 37
Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes
Xue R., Chen L., Zhang C., Fujita M., Li R., Yan S., Ong C.K., Liao X., Gao Q., Sasagawa S., Li Y., Wang J., Guo H., Huang Q., Zhong Q., et. al.
Q1 Cancer Cell 2019 цитирований: 62
Long non‑coding RNA UCA1 promotes proliferation and invasion of intrahepatic cholangiocarcinoma cells through targeting microRNA‑122
Li O., Yi W., Yang P., Guo C., Peng C.
Q4 Experimental and Therapeutic Medicine 2019 цитирований: 2
A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA
He J., Zuo Q., Hu B., Jin H., Wang C., Cheng Z., Deng X., Yang C., Ruan H., Yu C., Zhao F., Yao M., Fang J., Gu J., Zhou J., et. al.
Q1 Cancer Letters 2019 цитирований: 45
Regulatory roles of long noncoding RNAs implicated in cancer hallmarks
Wang J., Zhang X., Chen W., Hu X., Li J., Liu C.
Q1 International Journal of Cancer 2019 цитирований: 49
The Role of MicroRNAs in Hepatoblastoma Tumors
Cristóbal I., Sanz-Álvarez M., Luque M., Caramés C., Rojo F., García-Foncillas J.
Q1 Cancers 2019 цитирований: 16
Open Access
Open access
Functions and roles of long noncoding RNA in cholangiocarcinoma
Li J., Huang L., Li Z., Zhong X., Tai S., Jiang X., Cui Y.
Q1 Journal of Cellular Physiology 2019 цитирований: 13
Метрики

Поделиться

Цитировать
ГОСТ |
Цитировать
1. Burenina O.Y. и др. Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors // Journal of Cancer Research and Clinical Oncology. 2020. Т. 147. № 1. С. 49–59.
RIS |
Цитировать

TY - JOUR

DO - 10.1007/s00432-020-03378-5

UR - http://dx.doi.org/10.1007/s00432-020-03378-5

TI - Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors

T2 - Journal of Cancer Research and Clinical Oncology

AU - Burenina, Olga Y.

AU - Lazarevich, Natalia L.

AU - Kustova, Inna F.

AU - Shavochkina, Daria A.

AU - Moroz, Ekaterina A.

AU - Kudashkin, Nikolay E.

AU - Patyutko, Yuriy I.

AU - Metelin, Alexey V.

AU - Kim, Eduard F.

AU - Skvortsov, Dmitry A.

AU - Zatsepin, Timofei S.

AU - Rubtsova, Maria P.

AU - Dontsova, Olga A.

PY - 2020

DA - 2020/09/12

PB - Springer Science and Business Media LLC

SP - 49-59

IS - 1

VL - 147

SN - 0171-5216

SN - 1432-1335

ER -

BibTex |
Цитировать

@article{2020,

doi = {10.1007/s00432-020-03378-5},

url = {https://doi.org/10.1007%2Fs00432-020-03378-5},

year = 2020,

month = {sep},

publisher = {Springer Science and Business Media {LLC}},

volume = {147},

number = {1},

pages = {49--59},

author = {Olga Y. Burenina and Natalia L. Lazarevich and Inna F. Kustova and Daria A. Shavochkina and Ekaterina A. Moroz and Nikolay E. Kudashkin and Yuriy I. Patyutko and Alexey V. Metelin and Eduard F. Kim and Dmitry A. Skvortsov and Timofei S. Zatsepin and Maria P. Rubtsova and Olga A. Dontsova},

title = {Panel of potential {lncRNA} biomarkers can distinguish various types of liver malignant and benign tumors}

}

MLA
Цитировать
Burenina, Olga Y. et al. “Panel of Potential lncRNA Biomarkers Can Distinguish Various Types of Liver Malignant and Benign Tumors.” Journal of Cancer Research and Clinical Oncology 147.1 (2020): 49–59. Crossref. Web.